Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProBioGen, a technology and service provider for the development and production of biopharmaceutical drug substances, has entered into a contract with US-based biopharmaceutical development company Virdante Biopharmaceuticals.
Subscribe to our email newsletter
ProBioGen is expected to contribute producer cell line development and process engineering for one of Virdante’s proprietary therapeutic proteins.
Virdante Pharmaceuticals claimed that the protein products are unique in that they incorporate Virdante’s proprietary ‘Sialic Switch’ technology that improves the anti-inflammatory properties of an antibody for autoimmune and inflammatory diseases.
Virdante Pharmaceuticals selected ProBioGen for its expertise in developing royalty-free pharmaceutical cell lines and robust, economical processes for GMP-manufacturing.
Volker Sandig, chief scientific officer of ProBioGen, said: “We are highly impressed by Virdante´s products and strategies and their compelling scientific rationale to improve human proteins. We are excited to contribute our knowledge in harnessing the cellular machinery to maximize productivity for this ambitious project.”